Study Summary
This trial is testing two drugs to see how they affect blood vessels in people with pulmonary hypertension.
Eligible Conditions
- Pulmonary Hypertension
Treatment Effectiveness
Effectiveness Progress
This is further along than 93% of similar trials
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: Pre-pulmonary vasodilator testing measurements (baseline) will be compared to post-pulmonary vasodilator testing measurements during diagnostic right heart catheterization.
Pre-pulmonary vasodilator testing measurements (baseline) will be compared to post-pulmonary vasodilator testing measurements during diagnostic right heart catheterization.
Change in mean pulmonary artery pressure
Trial Safety
Safety Progress
This is further along than 85% of similar trials
Trial Design
2 Treatment Groups
Inhaled Nitric Oxide
1 of 2
Inhaled Epoprostenol
1 of 2
Active Control
Experimental Treatment
108 Total Participants · 2 Treatment Groups
Primary Treatment: Vasodilator testing (Inhaled Epoprostenol) · No Placebo Group · Phase 4
Inhaled Epoprostenol
Drug
Experimental Group · 1 Intervention: Vasodilator testing (Inhaled Epoprostenol) · Intervention Types: DrugInhaled Nitric Oxide
Drug
ActiveComparator Group · 1 Intervention: Vasodilator testing (Inhaled Nitric Oxide) · Intervention Types: DrugTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: pre-pulmonary vasodilator testing measurements (baseline) will be compared to post-pulmonary vasodilator testing measurements during diagnostic right heart catheterization.
Who is running the clinical trial?
Brigham and Women's HospitalLead Sponsor
1,498 Previous Clinical Trials
10,483,063 Total Patients Enrolled
Aaron B Waxman, MDPrincipal InvestigatorBrigham and Women's Hospital
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: